← Leaderboards
Kristen Leann Gullo
Us Worldmeds, Llc
$6,476,657
Attributed
$9,153,314
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.4M · FY2018–21$10M$7.5M$5M$2.5M$0
'18
'19
'20
'21
Funding mix
By agency
NIH$9,153,314 · 2
By mechanism
UG3$5,353,314 · 1
R01$3,800,000 · 1
Top collaborators
- Randal Seburg1 shared
Most similar at Us Worldmeds, Llc
Same institution · by research overlap
- Charles W. Gorodetzky$20,848,803
- James Alvan Longstreth$2,540,867
Others in their field
Other Emerging Leaders on “Formulation”
- Matthew Johnson · Duke University$56,071,536
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Xinhua Li · Nano Terra, Inc.$35,520,438
- Nader Fotouhi · Global Alliance For Tb Drug Development$28,468,137
- Jay Evans · University Of Montana$27,950,292
- Kristin Aillon · Midwest Research Institute$24,965,877
Research focus
FormulationIncidenceDoseExposure ToGeneral PopulationHealthcare SystemsAdultCytoplasmic GranulesCollaborationsEpidemicBiological AvailabilityBirthDistressHealth Care CostsBrainCare CostsCaringClinical TrialsAdrenergic AgonistsChildhoodCostDrug KineticsClinical ResearchInfant
Grant awards (4)
Development of Lofexidine as a First-line Non-Opioid Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome$5,353,314
UG3 · FY2021 · DA · contact PI
Accelerated Development of Lofexidine for Neonatal Opioid Withdrawal Syndrome$800,000
R01 · FY2020 · DA · contact PI
Accelerated Development of Lofexidine for Neonatal Opioid Withdrawal Syndrome$2,330,000
R01 · FY2019 · DA · contact PI
Accelerated Development of Lofexidine for Neonatal Opioid Withdrawal Syndrome$670,000
R01 · FY2018 · DA · contact PI